The global drug discovery market is expected to reach $68bn in 2028, according to a Visiongain report, with revenue gains driven by flexibility, agility, and the ability to innovate, says Evotec executive.
Repositive ‘increases visibility’ while ‘maintaining confidentiality’ as it makes its directory of preclinical cancer models publicly browsable as part of the relaunch of its Cancer Models Platform.
Notocord, an Instem company, will provide data acquisition and analysis services to a research and innovation program to improve risk prediction of cardiovascular adverse events.
Lovelace Biomedical leads a collaboration with The Jackson Laboratory, Exemplar Genetics, Iontox, and the University of Pennsylvania as part of a $20m contract with the NIH.
WuXi Clinical is expanding therapeutically - investing ‘heavily’ in oncology, CNS, GI - and plans to continue growing geographically as well, with a mission to bridge the gap between China and the rest of the world.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
LabCorp participated in a $3m Series B2 financing round for Kiyatec, which is developing ex vivo 3D cell culture technology to help model and predict cancer patients’ response to drug therapies.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
Celgene, Triphase Accelerator, and Facit entered a collaboration for a first-in-class preclinical therapeutic, targeting the WDR5 protein for the treatment of leukemia and other blood cancers.
Sanofi will use AbSci’s platform to further optimize two of its in-house proteins – and will partner with other companies to accelerate timelines and reduce costs.
Schrödinger closed an $85m (€74) financing round to support an expansion of its computational platform and drug discovery pipeline for internal and external use.
The new “groundbreaking” model can translate the results of mouse experiments into the equivalent human condition, outperforming traditional methods of extrapolation by up to 50%, say researchers.
The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.
InvVax’s universal flu vaccine candidate has demonstrated preclinical success as the company prepares for a Phase I clinical trial, supported by a Series A fundraising round.
